These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27689475)

  • 1. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
    Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
    Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
    Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Prognostic Relevance of Promoter DNA Methylation of
    Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
    Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
    Li X; Zhang W; Song J; Zhang X; Ran L; He Y
    Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
    Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
    Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
    Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
    Li Y; Meng L; Shi T; Ren J; Deng Q
    Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
    Kojima K; Yamashita K; Ushiku H; Katoh H; Ishii S; Tanaka T; Yokoi K; Suzuki M; Ooizumi Y; Igarashi K; Hosoda K; Moriya H; Mieno H; Katada N; Tanabe S; Watanabe M
    Dis Esophagus; 2017 Mar; 30(3):1-9. PubMed ID: 28184414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.